A 24-WEEK RANDOMIZED, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 17 YEARS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY)
Latest Information Update: 12 Dec 2022
At a glance
- Drugs Fesoterodine (Primary) ; Oxybutynin
- Indications Neurogenic bladder; Overactive bladder
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 26 Feb 2020 Status changed from recruiting to completed.
- 19 Feb 2020 Planned End Date changed from 14 Feb 2020 to 13 Feb 2020.
- 27 Jan 2020 This trial has been completed in Lithuania, according to European Clinical Trials Database.